I feel a lot better today after the dr been interview last night and the 2nd PR further explaining the situation. It is clear leronlimab works is a broad spectrum of patients. This is huge info, this drug is not specific to a narrow symptom or patient condition, it works. The problem is that we had too small of a trial and the wrong PE. Many here have raised the concern about the arbitrary 28 day mortality and its problems. Few here realized (including myself) that when you have a relatively small trial, the range of patient recruitment leads to in related comparisons and making it difficult to present a conclusive apples to apples assessment. If this was a 1000+ patient trial, we would not have the problem with too many over 65 on treatment and too few in placebo. We essentially have a phase 2 trial with a ton of solid data. Any way the data was sliced, leronlimab works. The fact that we might need to add 140 patients is extremely encouraging. It says the FDA gets it, they just need the trial to have a end conclusion that allows them to approve. They know the drug works. We also don’t know if this added protocol is even needed, the higher ups are looking at this and they are the ones to bend the rules. Nader is just following the rules.
If we had a larger trial that could lead to approval, we would be still enrolling today. With this data out, I think it will be easy to enroll. It will take a couple months, but we know it will work, there is no guessing.
Also, compare this situation to all other treatment options. Those trials had to be mined to get some showing of effectiveness. With CD12, no matter how you look at it the drug works, the trial design is the problem that prevents the P value. The extension is purely to fix the trial problem, not to twist the data to make a drug that does not work look like it does.
Let’s also keep in mind, the data is out, anyone from the medical community and the BP world can see this drug just proved it is not just an HIV drug. BP now has the luxury of approaching cytodyn knowing they both know what leronlimab can do. The very near term data from Nash and the cancer basket trial will really put the spotlight on this. The world does not need to understand, the industry now does.
Category: EconomyTotal Views: 92 By : EditorUpdated: 06-16-2024
Peru's GDP Surges by 5.28% in April
April's gross domestic product of Peru rose by 5.28% over the same month the year before. The nation's growth rate hasn't been this high in more than 2.5 years. The notable increase undid the contraction of the previous month. Though analysts had projected a far lower growth rate of 1.4%, Peru's economy outperformed these projections. Additionally surpassed was the government's goal of 4% growth. Peru's economy has shown resilien... Continue Reading
Category: MarketsTotal Views: 118 By : EditorUpdated: 06-16-2024
Stocks Conclude Last Week with Record Highs
Softer-than-expected inflation data helped stocks close last week strongly. Over 3% was gained by the Nasdaq Composite, and over 1.5% by the S&P 500. This lifted the S&P 500 above 5,400 for the first time ever. Four days running, the S&P 500 and Nasdaq closed at all-time highs. The Dow Jones Industrial Average, though, dropped by more than 0.7%. Regarding possible interest rate reductions, investors have hope. This hope propelled the mar... Continue Reading
Category: EconomyTotal Views: 116 By : EditorUpdated: 06-16-2024
Consumer Spending Trends in 2024
The patterns of consumer spending in 2024 are indicating consistent increase. Households are spending more money in spite of the uncertain economic times. Better consumer confidence and more disposable incomes are the main forces behind this expansion. This tendency is helping the retail industries, especially internet shopping. Both companies and governments are keeping a close eye on these trends to modify tactics. Sustaining economic growth requires knowled... Continue Reading
Category: StocksTotal Views: 165 By : EditorUpdated: 06-16-2024
Introduction to the AI Boom's Impact on Tech Stocks
Fundamentally changing the tech stock scene is the AI boom. Long the dominant software stocks, they are now under a lot of pressure. By contrast, the quick uptake of AI technologies is driving up demand for hardware stocks. This change has forced an assessment of investment approaches. AI involvement of tech companies is becoming more and more important to their performance. AI infrastructure suppliers, such GPU chip makers, are benefiti... Continue Reading
Category: StocksTotal Views: 150 By : EditorUpdated: 06-16-2024
Introduction to Fang Cheng Bao's Latest Model: The Bao 3
The latest model from BYD Co., Ltd.'s sub-brand Fang Cheng Bao is called the Bao 3. With an eye toward expanding its market share in electric vehicles, the brand has taken a big step with this model. The production version of the Super 3 concept, the Bao 3 showcases technological and design developments. Fang Cheng Bao is positioned by BYD to appeal to customers looking for unique and customised car options. The release fits nic... Continue Reading
Category: BusinessTotal Views: 158 By : EditorUpdated: 06-16-2024
Jeff Bezos' Long-Term Vision for Whole Foods
With his handling of Whole Foods, Jeff Bezos showed a strategic vision. His priorities were long-term gains over quick money. This required coming to choices that would eventually help the business. Among his tactics was to cut costs in order to keep clients. Bezos saw how crucial consumer loyalty was to the grocery industry. Enhancing operational effectiveness was another point he stressed as supporting this goal. For Whole Foods, under Amazon... Continue Reading
Through safe APIs, banks that participate in open banking exchange client data with outside vendors, so promoting financial services innovation and competition. It gives customers more control over their financial information and choices and, by tight regulations, guarantees security and privacy for them. Because it gives underprivileged people specialized services and presents enormous chances for small businesses, open banking also improves financial inclusion. Further innovation is expected f... Continue Reading
Category: EconomyTotal Views: 150 By : EditorUpdated: 06-16-2024
Interest rate reductions are about to happen by global central banks in reaction to different economic pressure. Depending on inflation trends, the Federal Reserve should start cutting by the end of June. To counter economic downturns and disinflation, the Bank of England and the European Central Bank might lower rates sooner. Additionally expected to lower rates in order to promote growth and stabilize their economies are emerging markets like Mexico and Brazil. These choices show customized ap... Continue Reading
Category: MarketsTotal Views: 163 By : EditorUpdated: 06-15-2024
Record-Setting Rally in the S&P 500
This year has seen multiple all-time highs for the S&P 500; almost thirty days have set records. Four record highs just in the last week continued this trend. The robust market is reflected in the previously unheard-of equity wealth of investors. Still, doubts have been aroused by the market's steady rise. Eight out of the previous ten trading days have seen the S&P 500 move less than 0.3%, suggesting stability. Investor worry is still raise... Continue Reading
Category: InvestingTotal Views: 287 By : EditorUpdated: 06-15-2024
Dow Jones Futures Sunday Evening Open
Together with the S&P 500 and Nasdaq futures, Dow Jones futures will open on Sunday night. Watching these futures closely to determine the direction of the market are investors. The action of the futures over night does not always portend the trading session that follows. Still, it gives light on investor mood and possible market swings. Analysts will be keeping a tight eye on these futures to see how big stocks like Apple, Nvidia, and Microsoft might... Continue Reading